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We have investigated the physiological signiﬁcance of the glucosylation of ceramides and the subsequent
deglucosylation of glucosylceramide in the synthetic pathway of acylceramide. In this metabolic pathway using
[14C]-serine in organ culture, newborn murine (BALB/c) epidermis synthesizes several types of ceramides,
including acylceramide, as analyzed by thin-layer chromatography. When conduritol-B-epoxide, a speciﬁc inhibitor
of b-glucocerebrosidase, was added to the culture medium, the synthesis of acylceramide was signiﬁcantly sup-
pressed in concert with a signiﬁcant increase in acylglucosylceramide. Furthermore, addition of D-threo-1-phenyl-
2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosyltransferase, also speciﬁcally abolished the
synthesis of acylceramide whereas non-acylated ceramides were relatively less affected. We further determined
whether the physiological substrate of glucosyltransferase is x-hydroxyceramide (C30) or non-x-hydroxylated
ceramides. Of those, only non-x-hydroxylated ceramides proved to be good substrates for glucosyltransferase
in vitro. Our parallel in vitro study also demonstrated that murine epidermis contains enzymatic activity by which
x-hydroxyglucosylceramide or x-hydroxyceramide can be converted to acylglucosylceramide or acylceramide.
Collectively, these ﬁndings indicate that the majority of acylceramides found in the stratum corneum may be
synthesized through a distinct sequence of enzymatic reactions consisting of the glucosylation of ceramides by
glucosyltransferase, x-hydroxylation of glucosylceramide, the acylation of x-hydroxyglucosylceramide (possibly
by an x-acyltransferase), and the deglucosylation of acylglucosylceramide by b-glucocerebrosidase.
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Acylceramides, especially those bearing linoleic acid as
their acyl moiety, are well known to play an essential role in
the barrier function of the stratum corneum (Melton et al,
1987; Imokawa et al, 1994). The central role of acylceramide
in barrier maintenance is corroborated by clinical evidence
that acylceramide levels are the most markedly reduced
among various species of ceramides in the stratum
corneum from patients with atopic dermatitis (AD) (Imokawa
et al, 1991). AD results from defects of the skin barrier
function as revealed by a markedly enhanced transepider-
mal water loss (Imokawa, 1999), which is considered to be
an etiologic factor in the recurrence of dermatitis (Imokawa,
2001) and for abnormalities of cutaneous immunology
(Kondo et al, 1998). This acylceramide deficiency, together
with the decreased bulk of ceramides, is thought to be a
major causative factor for the barrier disruption of the skin
observed in AD (Imokawa, 1999). This is also consistent
with studies showing that in essential fatty acid-deficient
rats, topical application of a synthetic pseudo-linoleic acid
bearing acylceramide leads to the complete restoration of
the disrupted barrier function of the skin (Imokawa et al,
1994). Similarly, synthetic pseudo-acylceramide has a
significant potential to repair the barrier disruption seen in
AD skin, which is accompanied by the clinical improvement
of atopic dry skin (Umeda et al, 1997). This close relation-
ship between barrier homeostasis and acylceramide
prompted us to seek the biochemical mechanism(s) under-
lying the acylceramide deficiency of AD.
As for the mechanism(s) involved in the ceramide
deficiency seen in AD, we have previously reported that
sphingomyelin deacylase is abnormally expressed in the
epidermis of AD patients (Murata et al, 1996; Hara et al,
2000; Higuchi et al, 2000). That enzyme hydrolyzes
sphingomyelin at the acyl site to yield sphingosylpho-
sphorylcholine rather than ceramides (which would normally
be produced by sphingomyelinase). This can reasonably
account for the mechanism of ceramide deficiency, which is
attributable to abnormalities of sphingomyelin hydrolysis.
This however does not account for the acylceramide
deficiency because it has been reported that the o-
hydroxyceramide species necessary for the synthesis of
Abbreviations: AD, atopic dermatitis; CBE, conduritol-B-epoxide;
4-MUG, 4-methylumbelliferyl-D-b-glucoside; PDMP, D-threo-1-phe-
nyl-2-decanoylamino-3-morpholino-1-propanol.
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acylceramide in mammalian stratum corneum is not derived
from sphingomyelin, suggesting that they are derived solely
from glucosylceramide precursors (Uchida et al, 2000).
In contrast to the biosynthesis of ceramides, which
involves hydrolysis by sphingomyelinase (Schmuth et al,
2000) or by b-glucocerebrosidase (Holleran et al, 1994;
Takagi et al, 1999), little is known about the biosynthetic
pathway of acylceramides because multiple steps are
required for their biosynthesis. Thus, acylceramides can
be synthesized by several possible pathways (as shown in
Fig 1) and there are at least three reaction sequences that
can lead to their biosynthesis, including (1) the o-hydro-
xylation of ceramide and its subsequent acylation, (2) the
glucosylation of ceramide and its subsequent o-hydroxyla-
tion followed by acylation and deglucosylation, and (3) the
o-hydroxylation of ceramide, and its acylation followed
by glucosylation and deglucosylation, or glucosylation
followed by acylation and deglucosylation. Recently, based
upon findings on alkyl chain moieties of sphingomyelin, it
has been speculated that acylceramides are not derived
from sphingomyelin by the action of sphingomyelinase
(Uchida et al, 2000). Epidermal enzymes with o-hydroxylase
activity have been reported to exist in mammalian epidermis
and are likely to be identical to cytochrome P-450 (Behne
et al, 2000); however, it is still not completely clear, however,
whether glucosylation or deglucosylation is required for the
biosynthesis of acylceramide. It would also be of consider-
able interest to know whether an o-acyltransferase actually
exists in the epidermis which might be involved in the
biosynthesis of acylceramide and/or in the synthesis of
acylglucosylceramide from glucosylceramide. Such clarifi-
cations would provide important insights into the biosyn-
thetic pathway of acylceramide in the epidermis. In this
study therefore, we examined the effects of inhibitors
of glucosyltransferase or of b-glucocerebrosidase on the
biosynthesis of acylceramide in the organ-cultured epider-
mis of newborn mice. Further, we assessed the substrate
specificity of glucosyltransferase and identified an o-acyl-
transferase activity in murine epidermis. Our results indicate
that the majority of acylceramides found in the stratum
corneum may be synthesized through a distinct sequence
of enzymatic reactions involving the glucosylation of
ceramide by glucosyltransferase, the o-hydroxylation by
hydroxylase followed by o-hydroxyglucosylceramide (pos-
sibly by an o-acyltransferase), and the deglucosylation of
acylglucosylceramide by b-glucocerebrosidase.
Results
Speciﬁcity of inhibitors for b-glucocerebrosidase and
glucosyltransferase To determine the specificity of inhibi-
tors for b-glucocerebrosidase and for glucosyltransferase,
we measured the inhibitory effects of CBE or PDMP on their
catalytic activities. The results demonstrated that CBE or
PDMP specifically inhibit b-glucocerebrosidase or glucosyl-
transferase, respectively, and had little or no effect on the
other enzyme (Fig 2).
Effective inhibition of the synthesis of acylceramide To
determine the involvement of glucosylation and/or deglu-
cosylation by glucosyltransferase and b-glucocerebrosi-
dase, respectively, in the biosynthetic pathway of acyl-
ceramides, we examined the effects of PDMP or CBE on
that synthesis. When CBE (10 mM) was added to the
epidermal organ culture and lipids were radiolabeled with
Figure 1
Possible pathways of acylceramide bio-
synthesis. CoA, coenzyme A; G, Glucose;
CBE, conduritol-B-epoxide; PDMP, D-threo-
1-phenyl-2-decanoylamino-3-morpholino-
1-propanol.
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[14C]-serine, incorporation of [14C]-serine into all types of
ceramides, including acylceramide, separated by TLC was
significantly decreased (Figs 3 and 4). The level of acyl-
glucosylceramide however was significantly increased. In
contrast, the addition of PDMP (50 mM) significantly
decreased acylceramide levels in spite of a slight change
in non-acylated ceramides. In concert with that decrease in
acylceramide, glucosylceramide levels, including acylglu-
cosylceramide, were significantly decreased. Treatment of
the extracted lipid sample with mild alkali resulted in the
disappearance of the acylceramide and the acylglucosyl-
ceramide bands on the TLC plate (Fig 5). These results
suggest that both glucosylation and deglucosylation are
required for the biosynthesis of acylceramides.
Glucosyltransferase acts on ceramides but not on
x-hydroxyceramide Possible pathways involving glucosy-
lation and deglucosylation before acylceramide formation
are shown in Fig 1. The substrates for glucosyltransferase
may be either non-o-hydroxylated ceramides or o-hydro-
xyceramide, depending on where the o-hydroxylation step
occurs. To clarify the pathway(s) involved in the glucosyla-
tion, we tested whether o-hydroxyceramide can serve as a
substrate for glucosyltransferase. Analysis of [14C]-glucose-
labeled hydroxyceramide or ceramides following the enzy-
matic reaction revealed that whereas non-o-hydroxylated
ceramides (NS or AS) used as a control were significantly
glucosylated, the glucosylation rate of o-hydroxyceramide
was at a negligible level (Fig 6), indicating that it is not a
good substrate for glucosyltransferase. This result suggests
that the glucosylation by glucosyltransferase occurs with
ceramides prior to the synthesis of o-hydroxyceramide
during an early step in the biosynthetic pathway of
acylceramide.
Existence of x-acyltransferase in murine epidermis
Based upon the above findings, it seemed likely that
glucosylceramide generated by glucosyltransferase is con-
verted (possibly by the P-450 enzyme (Ortiz de Montellano,
1995)) to o-hydroxyglucosylceramide, which then under-
goes acylation by o-acyltransferase to yield acylglucosyl-
ceramide. Since there is no available evidence that an
Figure 2
Specificity of Inhibitors for b-glucocer-
ebrosidase and glucosyltransferase.
b-Glucocerebrosidase and glucosyl-
transferase activities were measured in
an epidermal extract using assay meth-
ods as described in Materials and Meth-
ods. Activity in the presence of each
inhibitor is expressed as relative activity
to control as 100%. (a) b-Glucocerebro-
sidase activity. (b) Glucosyltransferase
activity. The epidermal b-glucocerebro-
sidase and glucosyltransferase activities
were 2.4 nmol per mg per min and 2000
dpm per mg per min, respectively.
Figure 3
TLC development of [14C]-labeled
lipids in cultured murine epidermis.
Epidermal sheets were organ-cultured
for 16 h at 371C in MEM containing 92.5
kBq [14C]-serine and inhibitors as noted
at a concentration of 50 mM for PDMP
or 10 mM for CBE, homogenized, and
lipids were extracted as detailed in
Materials and Methods.
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o-acyltransferase exists in the epidermis, it is of consider-
able value to elucidate the possible activity of this enzyme.
To determine whether there is any detectable activity of
o-acyltransferase in the epidermis by which o-hydroxyglu-
cosylceramide would be converted to acylglucosylcera-
mide, we measured that activity in a homogenate of murine
epidermis. TLC analysis following enzymatic reaction
revealed that acylglucosylceramide is produced at signifi-
cant levels after incubation of the substrate with murine
epidermis (Fig 7a). In addition, there was no detectable
increase in the level of acylceramide during this reaction
(Fig 7a and b), which suggests that the formation of
acylglucosylceramide does not result from the three sequen-
tial reactions consisting of deglucosylation of o-hydroxygluco-
Figure 4
Suppression of the synthesis of
acylceramide by inhibitors. Radio-
active bands were quantified by
BAS2000. Values are mean of triplicate
assays  SD. (a) Incorporation of 14C-
serine into acylceramide. (b) Incor-
poration of 14C-serine into acylgluco-
sylceramide. (c) Incorporation of 14C-
serine into non-acylated ceramide. (d)
Incorporation of 14C-serine into non-
acylated glucosylceramide.
Figure 5
TLC analysis of radiolabeled acylceramide. TLC was developed
initially with chloroform:methanol:water (95:1:5, v/v/v), and then by
chloroform:methanol:acetone (76:20:4, v/v/v) as detailed in Materials
and Methods. Radioactive bands were visualized by a BAS2000
Imaging Analyzer. Figure6
Substrate specificity of x-hydroxy-ceramide (Cer(W)), ceramide
with non-hydroxy fatty acid, sphingosine base (Cer(NS)), and
ceramide with hydroxy fatty acid, sphingosine base (Cer(AS)) for
murine epidermal glucosyltransferase. (a) TLC development of radio-
labeled glucosylceramide. (b) Glucosyltransferase activity. Values are
means of triplicate assays  SD. Glucosyltransferase activity was
measured using non-o-hydroxylated ceramide or o-hydroxyceramide
as a reconstitution substrate as described in Materials and Methods.
The reaction products were separated with TLC (chloroform:methanol:
water (60:35:8, v/v/v) in a horizontal HPLC chamber and quantitated by
a BAS-2000 Imaging Analyzer.
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sylceramide, subsequent acylation, and glucosylation. As
a further confirmation, we measured the effect of inhibitors
for deglucosylation and glucosylation on the generation of
acylglucosylceramide. The conversion of o-hydroxyglucosyl-
ceramide to acylglucosylceramide was not abolished by either
inhibitor (Fig 7c), which suggests the direct conversion
described above. When o-hydroxyceramide was used as
a substrate, the formation of acylceramide was observed
(Fig 7b). These results strongly suggest the existence of an
o-acyltransferase in murine epidermis. Although o-hydroxy-
ceramide can also be converted to acylceramide by murine
epidermis under our experimental conditions, it seems
implausible that the conversion of o-hydroxyceramide by
o-acyltransferase to acylceramide substantially occurs in vivo
because both the glucosylation and the deglucosylation are
required for the synthesis of acylceramide.
Discussion
There are two pathways associated with the biosynthesis of
ceramides (including acylceramide) in the epidermis. One is
the pathway mediated by sphingomyelinase in which
sphingomyelin serves as the substrate (Schmuth et al,
2000). The other is the pathway involved with b-glucocer-
ebrosidase in which glucosylceramide serves as the
substrate (Takagi et al, 1999). The contribution of at least
these two pathways to the biosynthesis of ceramide at the
interface between the granular and the stratum corneum
layers is also corroborated by studies on Gaucher disease
(Sidransky et al, 1996) or Niemann–Pick disease (Schmuth
et al, 2000). These diseases are genetic disorders asso-
ciated with inherited deficiencies of b-glucocerebrosidase
or sphingomyelinase, respectively, where reduced levels of
ceramides still remain in the stratum corneum. Uchida et al
(2000) recently speculated that acylceramide is derived not
from sphingomyelin but from acylglucosylceramide by the
action of b-glucocerebrosidase, based upon the fact that
the amide-linked fatty acid moiety of sphingomyelin con-
tains no linoleic acid-esterified fatty acid or o-hydroxy fatty
acid. This speculation is also supported by the fact that, in
general, Gaucher disease has a more severe barrier defect
than Niemann–Pick disease (Sidransky et al, 1996; Schmuth
et al, 2000), which indicates the major contribution of the
acylceramide biosynthetic pathway to the hydrolysis via
b-glucocerebrosidase. Consistent with this speculation,
our study using an inhibitor of b-glucocerebrosidase
revealed that deglucosylation by b-glucocerebrosidase is
required for the biosynthesis of acylceramide. Because one
Figure7
Acyltransferase activity in murine epidermis. (a) TLC development of
radiolabeled acylglucosylceramide generated following incubation of
epidermal membrane fraction with o-hydroxyglucosylceramide (GlcCer(W))
used as a substrate. (b) TLC development of radiolabeled acylceramide
generated following incubation of epidermal membrane fraction with o-
hydroxyceramide used as a substrate. The reaction products were
separated with TLC (initially with chloroform:methanol:water (95:1:5, v/
v/v) followed by chloroform:methanol:acetone (76:20:4, v/v/v) or chlo-
roform:methanol:water (60:35:8, v/v/v) in a horizontal HPLC chamber
and quantitated by a BAS-2000 Imaging Analyzer. (c) Effects of
inhibitors for glucosylation and deglucosylation on acyltransferase
activity measured by radiolabeled acylceramide formation in murine
epidermis. Values are means of triplicate assays  SD. Inhibitors were
used at a concentration of 50 mM for PDMP or 10 mM for CBE. Activity
in the presence of each inhibitor is expressed as relative activity to
control as 100%, the activity of which was 3000 dpm per mg per min.
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substrate of b-glucocerebrosidase that leads to the gen-
eration of acylceramide is acylglucosylceramide, our study
using the glucosyltransferase inhibitor (which suggests that
glucosylation is also required for the biosynthesis of acyl-
ceramide) is very consistent with a possible pathway of
acylceramide biosynthesis. Thus, our study using inhibitors
of glucosyltransferase or b-glucocerebrosidase on the bio-
synthesis of acylceramide in organ-cultured murine epider-
mis clearly demonstrated that inhibiting glucosylation or
deglucosylation of ceramides significantly abolishes the
synthesis of acylceramide. Importantly, the inhibited bio-
synthesis of acylceramide was accompanied by the altered
biosynthesis of acylglucosylceramide, which was signifi-
cantly decreased by PDMP (an inhibitor of glucosylation)
but significantly accumulated by CBE (an inhibitor of
deglucosylation). As we could not rule out the possibility
that PDMP or CBE may inhibit o-hydroxylation, the fact that
the acylceramide biosynthesis is significantly downregu-
lated by either PDMP or CBE might minimize the contribu-
tion of inhibited o-hydroxylation by these inhibitors to the
downregulated biosynthesis of acylceramide. Although,
consistent with the in vivo study by Holleran et al (1994),
the biosynthesis of all types of ceramides is decreased by
the inhibition of deglucosylation, it should be noted that
the decreased level of acylceramide biosynthesis is much
higher than that of non-acylated ceramides. Collectively,
these findings strongly suggest that both glucosylation and
subsequent deglucosylation are essential requirements for
the biosynthesis of acylceramides found in the stratum
corneum.
While deglucosylation of acylglucosylceramide by b-
glucocerebrosidase can be reasonably considered the
final step leading to the biosynthesis of acylceramide, it
is intriguing to determine where the glucosylation occurs
during the multiple steps of acylceramide biosynthesis. Our
substrate specificity study revealed that the reactivity of
glucosyltransferase for o-hydroxyceramide was poor com-
pared to non-o-hydroxylated ceramides. Although a possi-
ble low solubility of o-hydroxyceramide might account for
this poor reactivity, in our study this o-hydroxyceramide
was found to be acylated to acylceramide by o-acyltrans-
ferase, which implies that o-hydroxyceramide may have a
solubility sufficient for the enzymatic reaction involving
glucosyltransferase. Our substrate specificity study thus
demonstrated the possibility that glucosylation by glucosyl-
transferase occurs at the ceramide moiety but hardly at the
o-hydroxyceramide moiety, which indicates that glucosyla-
tion may be an early biosynthetic process leading to the
acylceramide synthesis. Since this speculated process
requires substantial o-hydroxylation of glucosylceramide
leading to the final acylceramide synthesis, the conclusive
pathway remains unclear until the existence of enzymes
that catalyze the o-hydroxylation of glucosylceramide in the
epidermis will be eventually proved.
It has been speculated that o-hydroxylation of the free
fatty acid moiety is possibly converted by cytochrome
P-450 (Ortiz de Montellano, 1995). The inhibition of this
enzyme by a specific inhibitor, aminobenzotriazole (ABT),
has consistently been shown to lead to barrier disruption in
mammalian skin through deranged corneocyte lipid envel-
ope (CLE) formation and decreases in acylceramide
production (Behne et al, 2000), although that study did not
focus on the involvement of acylceramide in the barrier
disruption. That study also suggested that o-hydroxylation
is an essential requirement both for acylceramide synthesis
and for the formation of CLE. It remains to be clarified at
which steps during acylceramide biosynthesis o-hydroxyl-
ation occurs, and there is speculation showing that
o-hydroxylation precedes ceramide formation (Behne et al,
2000). Thus, it seems plausible that glucosylceramides
generated by glucosyltransferase are converted, possibly
by cytochrome P-450 (Ortiz de Montellano, 1995), to
o-hydroxyglucosylceramide, which then undergoes acyla-
tion by o-acyltransferase to yield acylglucosylceramide.
There have been no reports to date that show the existence
of an o-acyltransferase able to convert hydroxyglucosylcer-
amide to acylglucosylceramide in mammalian epidermis,
although the cloning and enzymatic characterization of a
1-O-acylceramide synthase has been established in bovine
brain (Hiraoka et al, 2002). Our study demonstrates that
murine epidermis contains enzymatic activity by which
o-hydroxyglucosylceramide can be converted to acylglu-
cosylceramide. This conversion was not abolished by
inhibitors for either glucosylation or deglucosylation, which
rules out the possible three step reactions other than the
direct acylation leading to the generation of acylglucosyl-
ceramide. Collectively, these findings strongly suggest the
existence of such an o-acyltransferase in the epidermis.
Although o-hydroxyceramide was found to be converted
to acylceramide by murine epidermis under our in vitro
conditions, it seems unlikely that the conversion of
o-hydroxyceramide by o-acyltransferase to acylceramide
substantially occurs in vivo, based upon the essential
requirement of both the glucosylation and the deglucosyla-
tion for the biosynthesis of the majority of acylceramides
found in the stratum corneum.
Recent studies revealed that o-hydroxyceramides are
ester linked by the action of the transglutaminase 1 enzyme
to glutamine and glutamate residues of a number of cell
envelope structural proteins, most notably involucrin, which
serve as cornified cell envelope bound-ceramides and thus
contribute to the barrier function of the epidermis (Marekov
and Steinert, 1998; Nemes et al, 1999). It remains unclear as
to whether the covalent attachment of o-hydroxyceramide
to cornified envelope proteins to form the CLE occurs with
free o-hydroxyceramide, the acylceramide species, and/or
with o-hydroxyglucosylceramide (Behne et al, 2000). Since
in the absence of b-glucocerebrosidase activity o-hydro-
xyglucosylceramide can be covalently linked to the cornified
cell envelope, it has been speculated that deglucosylation
may normally occur following CLE formation (Behne et al,
2000). Although in our study of organ-cultured epidermis
(which was not suitable for the detection of bound cera-
mides in the stratum corneum) we did not focus on the
formation of covalently bound o-hydroxyceramide, it would
be of considerable interest to determine the precise roles of
glucosylation and deglucosylation in the formation of CLE. It
should be noted that there is an accumulation of protein-
bound epidermal glucosylceramides in b-glucocerebrosi-
dase-deficient type 2 Gaucher mice (Doering et al, 1999).
In conclusion, the sum of these findings supports the
notion for the first time that the majority of acylceramides
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found in the stratum corneum may be synthesized through a
distinct sequence of enzymatic reactions consisting of the
glucosylation of ceramide by glucosyltransferase, followed
by o-hydroxylation, the subsequent acylation of glucosyl-
ceramide (possibly by an o-acyltransferase), and the degluco-
sylation of acylglucosylceramide by b-glucocerebrosidase.
Materials and Methods
Materials One to three day old male newborn BALB/c mice were
purchased from Charles River Japan, Kanagawa, Japan. [14C]-
UDP-glucose (11.1 GBq per mmol) was purchased from Amer-
sham International (Buckinghamshire, UK). L-[14C(U)]-serine (5.88G
Bq per mmol) and [14C]-linolenic acid (1.99 MBq per mmol) were
purchased from Perkin-Elmer Life Science, (Boston, Massachu-
setts). Ceramides (ceramide with non-hydroxy fatty acid, sphingo-
sine base (Cer(NS)) and ceramide with hydroxy fatty acid,
sphingosine base (Cer(AS)), prepared from bovine brain galacto-
sylceramide), glucosylceramide (prepared from human Gaucher’s
spleen), UDP-glucose, adenosine 50-triphosphate, PDMP (D-threo-
1-phenyl-2-decanoylamino-3-morpholino-1-propanol) (Inokuchi
and Radin, 1987), CBE (conduritol-B-epoxide (1,2-anhydro-myoi-
nositol)), taurodeoxycholate, 4-methylumbelliferone (4-MU), and 4-
methylumbelliferyl-b-D-glucoside (4-MUG) were purchased from
Sigma-Aldrich (St Louis, Missouri). HEPES (2-[4-(2-hydroxyethyl)-
1-piperazinyl]ethanesulfonic acid), MES (2-morpholinoethanesul-
fonic acid), and CHAPS (3-[(3-cholamidopropyl) dimethylammo-
nio]-1-propansulfonate) were purchased from Dojindo Laboratories
(Kumamoto, Japan). Acetyl coenzyme A was purchased from
Wako Pure Chemical Industries (Osaka, Japan). NADH (nicotina-
mide adenine dinucleotide) was purchased from ICN Biomedicals
(Aurora, Ohio). High-performance thin-layer chromatography
(HPTLC) plates were purchased from Merck (Darmstadt, Ger-
many). The BioRad Protein Assay Kit and bovine serum albumin
(BSA) were obtained from BioRad (Richmond, California). Glucosyl
b1-N-(o-OH)-triacontanoyl-eicosasphingenine (o-hydroxyglucosyl-
ceramide) and (o-OH)-triacontanoyl-eicosasphingenine (o-hydroxy-
ceramide) were synthesized according to the method of Mori and
Matsuda (1991). Other reagents were of the highest grade com-
mercially available.
Preparation of enzyme Skin samples were excised from newborn
mice after euthanization and the subcutaneous tissue was
removed by tweezers. Epidermal sheets were then obtained by
floating the skin in an EDTA solution (10 mM EDTA/PBS-Ca2þ /
Mg2þ free) at 371C for 60 min and gentle scraping with a scalpel
blade. The epidermis from each animal was homogenized in
0.5 mL homogenizing buffer (0.32 M sucrose, 0.25 mM DTT, 1 mM
EDTA (pH 7.4)) using a hand-driven glass homogenizer. Homo-
genates were centrifuged (800  g for 5 min) to remove unbroken
stratum corneum. A membrane fraction of murine epidermis
obtained by centrifugal fractionation (104  g, 30 min) was
prepared from the homogenate and membrane-bound proteins
were solubilized with CHAPS. The concentrations of protein and
CHAPS were 4 mg per mL and 2%, respectively. After solubiliza-
tion at 01C for 1 h, the solubilized fraction was obtained by
centrifugation at 105  g for 1 h. The reconstitution method was
performed basically as described previously (Radian and Kanner,
1985).
Protein concentrations were measured using the BioRad
Protein Assay Kit with BSA as a standard.
Enzyme assays
UDP-glucose: ceramide glucosyltransferase The glucosyltransfer-
ase enzyme assay was carried out by a modified assay method
with micellar system (Coste et al, 1985). The reaction mixture
contained enzyme (125–200 mg protein), 20 mg ceramide or
o-hydroxyceramide, 6.25 nmol [14C]-UDP-glucose (13.9 kBq), 5.5
mol MES (pH 6.4), 550 nmol MnCl2, 275 nmol MgCl2, 110 nmol
NADH, 550 nmol DTT, and 1% CHAPS, in a final volume of 110 mL.
Reactions were carried out at 371C for 30 min. The reactions were
terminated by the addition of methanol, and total lipids were
extracted by the method of Bligh and Dyer (1959). The reaction
products were separated by TLC (chloroform:methanol: water¼
60:35:8 (v/v/v) in a horizontal HPLC chamber (Camag, Muttenz,
Switzerland)) and were quantitated using an imaging analyzer
(BAS-2000, Fuji Photofilm, Tokyo, Japan).
b-Glucocerebrosidase The b-glucocerebrosidase enzyme assay
was carried out as described previously (Holleran et al, 1992). In
brief, all assays were carried out for 60 min at 371C in citrate–
phosphate buffer (pH 5.6) with 5 mM sodium taurodeoxycholate as
the assay buffer and 0.5 mM 4-MUG as substrate. Enzyme solution
(50 mL) in assay buffer was pre-heated in a siliconized glass culture
tube, and the reaction was initiated by the addition of 50 ml
substrate solution in assay buffer. The reaction was terminated by
the addition of 1.25 mL of 200 mM carbonate–bicarbonate buffer
(pH 10.5). The fluorescence was measured (Ex¼ 360 nm, Em¼ 450
nm) with a Perkin-Elmer spectrofluorimeter. A standard 4-MU
solution (0–300 nM) in carbonate–bicarbonate buffer was used for
calibration.
Acyltransferase activity The reaction mixture contained the en-
zyme source (approximately 20 mg protein), 20 mg o-hydroxyglu-
cosylceramide or o-hydroxyceramide, [14C]-linoleic acid (3.7 kBq),
550 nmol MnCl2, 275 nmol MgCl2, 110 nmol NADH, 550 nmol DTT,
5.5 mmol MES (pH 6.4), 500 nmol ATP, 250 nmol CoA-SH, and 1.1
mg CHAPS in a final volume of 110 ml. Reaction mixtures were
incubated at 371C for 1 h. This reaction utilizes endogenous acyl
CoA synthase for the synthesis of linoleoyl CoA. The reactions
were stopped by the addition of methanol and total lipids were
extracted by the method of Bligh and Dyer (1959) and analyzed by
HPTLC, as described above.
Mild alkali treatment Extracted lipids were treated with 1 mL
chloroform:methanol:10 M NaOH (2:7:1, v/v/v) at 371C for 1 h. After
this treatment, the Bligh and Dyer (1959) extraction method was
performed.
Analysis of acylceramide synthesis in murine epidermis Four
epidermal sheets (5  5 mm), prepared from newborn mice as
described above, were incubated in 1 mL MEM (Sigma-Aldrich)
containing 10% dialyzed FCS, 92.5 kBq [14C]-serine and various
inhibitors in 5% CO2/95% air for 16 h at 371C. After incubation,
epidermal sheets were homogenized in solvent (chloroform:
methanol:water¼ 1:2:0.8, v/v/v) and lipids were extracted by the
Bligh and Dyer (1959) method.
TLC analysis The lipids and reaction products extracted were
analyzed by HPTLC according to the method of Ponec et al (1988).
TLC was developed in a horizontal TLC chamber (Camag, Muttenz,
Switzerland) with chloroform:methanol:water (95:1:5, v/v/v) (10 cm
from the origin). An additional separation was then achieved by
developing the plate in the same direction (2.5 cm from the origin)
with chloroform:methanol:acetone (76:20:4, v/v/v) (Ponec et al,
1988). Radioactive bands were visualized and quantified by
BAS2000 (Fuji Photofilm, Tokyo, Japan). TLC plates were also
chemically visualized by spraying with H2SO4 followed by heating
at 1101C for 10 min.
DOI: 10.1111/j.0022-202X.2004.22307.x
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